Pathos is a biotechnology company that leverages AI to accelerate oncology drug development.
Pathos has raised $365.0M in total funding. The most recent round was Series D. The last funding was announced in May 2025.
Pathos's investors include New Enterprise Associates, Builders VC, Lightbank, Revolution Growth.
Pathos is headquartered in Chicago, United States.
Pathos is a biotechnology company that leverages AI to accelerate oncology drug development.
Pathos is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pathos — Funding & Investors." VCBacked, May 15, 2025, https://www.vcbacked.co/company/pathos. Accessed September 14, 2026.
VCBacked. (2025). Pathos — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/pathos
{{cite web |title=Pathos — Funding & Investors |url=https://www.vcbacked.co/company/pathos |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated